News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CombiMatrix Corporation (CBMX) Partners With Clarient, Inc. to Commercialize CombiMatrix Genomic Profile Tests for Cancer



4/11/2011 9:54:27 AM

IRVINE, Calif., April 11, 2011 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) announced today that it has entered into a strategic partnership with Clarient, Inc., a GE Healthcare Company, that allows Clarient the right to commercialize the CombiMatrix DNAarray™ product portfolio. The DNAarray tests are based on aCGH technology, which provides physicians a comprehensive genomic profile of solid cancer tumors and blood-based cancers, helping to better guide patient treatment decisions.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES